<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"><channel><title>The Long Dawn</title><link>https://thelongdawn.pages.dev/</link><description>A living record of the trials lengthening human life. Not medical advice.</description><language>en</language><item><title>ERAS&#8209;0015 shrank tumours in early pancreatic and lung cancer testing</title><link>https://thelongdawn.pages.dev/d/eras-0015-ras-glue-early-results/</link><guid>https://thelongdawn.pages.dev/d/eras-0015-ras-glue-early-results/</guid>
<pubDate>Fri, 20 Nov 2026 12:00:00 +0000</pubDate><description>Phase 1 · Company-reported · not peer reviewed. Erasca, a San Diego drugmaker, reported early results for ERAS&#8209;0015, a once-daily pill aimed at mutant RAS, the driver found in about 95% of pancreatic cancers. As reported by CTV News: tumours shrank substantially in 44% of 25 people with advanced pancreatic cancer on a 32 mg daily dose, and in 3 of 5 people with lung cancer who had already had immunotherapy and chemotherapy. Erasca says late-stage trials of ERAS&#8209;0015 and a second drug, ERAS&#8209;4001, start in 2027. Princess Margaret Cancer Centre in Toronto is expected to be a site.</description></item><item><title>First treatment approved for the neurological symptoms of type 3 Gaucher disease</title><link>https://thelongdawn.pages.dev/d/venglustat-gaucher-type-3-brain/</link><guid>https://thelongdawn.pages.dev/d/venglustat-gaucher-type-3-brain/</guid>
<pubDate>Wed, 18 Nov 2026 12:00:00 +0000</pubDate><description>Approved · Regulator decision. The FDA approved Infilbray (venglustat, Sanofi&#x27;s Genzyme) tablets on 18 Nov 2026 for the neurological symptoms of type 3 Gaucher disease in people weighing at least 15 kg. In a randomized, double-blind study of 43 patients aged 12 and over, people on venglustat did better at week 52 on a combined measure of coordination and thinking than people on enzyme replacement therapy. Enzyme replacement treats the body but does not reach the brain; venglustat does.</description></item><item><title>First drug shown to help children with infantile-onset Niemann-Pick disease type C live longer</title><link>https://thelongdawn.pages.dev/d/adrabetadex-niemann-pick-c-survival/</link><guid>https://thelongdawn.pages.dev/d/adrabetadex-niemann-pick-c-survival/</guid>
<pubDate>Tue, 17 Nov 2026 12:00:00 +0000</pubDate><description>Approved · Regulator decision. The FDA approved Lembaz (adrabetadex) on 17 Nov 2026 to reduce the risk of death in people with Niemann-Pick disease type C whose neurological symptoms began before age 6. Across three studies and an expanded access program, 36 treated patients had a 55% lower risk of death than a matched external control group. Median survival was 8.5 years versus 4.9 years. It is given into the spinal canal every two weeks by a trained provider.</description></item><item><title>FDA grants accelerated approval to neladalkib for ALK-positive lung cancer after earlier therapy</title><link>https://thelongdawn.pages.dev/d/neladalkib-alk-lung-cancer/</link><guid>https://thelongdawn.pages.dev/d/neladalkib-alk-lung-cancer/</guid>
<pubDate>Tue, 17 Nov 2026 12:00:00 +0000</pubDate><description>Approved · Regulator decision. On 17 Nov 2026 the FDA granted accelerated approval to neladalkib (Nelkarmi, Nuvalent) for adults with locally advanced or metastatic ALK-positive non-small cell lung cancer. It is for people previously treated with alectinib, or with two or more ALK inhibitors plus platinum chemotherapy.</description></item><item><title>First factor XIa blood thinner approved to cut the risk of a second stroke</title><link>https://thelongdawn.pages.dev/d/asundexian-factor-xia-stroke-prevention/</link><guid>https://thelongdawn.pages.dev/d/asundexian-factor-xia-stroke-prevention/</guid>
<pubDate>Mon, 09 Nov 2026 12:00:00 +0000</pubDate><description>Approved · Regulator decision. The FDA approved Sunharbo (asundexian 50 mg, Bayer) on 9 Nov 2026, taken with antiplatelet therapy after a recent mild-to-moderate non-cardioembolic stroke or a high-risk mini-stroke (TIA). In the phase 3 OCEANIC-STROKE trial of 12,327 adults, it reduced the risk of ischemic stroke by 26% versus placebo over a median of 14.2 months. Major bleeding overall was similar to placebo.</description></item><item><title>First plasmid DNA immunotherapy approved in the US, for a rare HPV airway disease</title><link>https://thelongdawn.pages.dev/d/voceryq-plasmid-dna-immunotherapy-rrp/</link><guid>https://thelongdawn.pages.dev/d/voceryq-plasmid-dna-immunotherapy-rrp/</guid>
<pubDate>Fri, 30 Oct 2026 12:00:00 +0000</pubDate><description>Approved · Regulator decision. The FDA granted accelerated approval on 30 Oct 2026 to Voceryq for adults with recurrent respiratory papillomatosis, wart-like airway growths caused by HPV types 6 and 11. It delivers two DNA plasmids, one carrying HPV protein instructions and one an immune booster (IL&#8209;12), into muscle cells using brief electrical pulses. In an open-label trial of 32 adults, 7 of 26 people who had needed at least three prior surgeries needed none in the year after treatment.</description></item><item><title>Clot removal 24 to 72 hours after a major stroke improved recovery, with more bleeding</title><link>https://thelongdawn.pages.dev/d/late-mt-thrombectomy-24-72-hours/</link><guid>https://thelongdawn.pages.dev/d/late-mt-thrombectomy-24-72-hours/</guid>
<pubDate>Fri, 23 Oct 2026 12:00:00 +0000</pubDate><description>Phase 3 · Peer-reviewed journal. The LATE-MT randomized trial in China enrolled 336 people with a large-vessel stroke and brain tissue still salvageable on imaging, 24 to 72 hours after onset. Adding endovascular clot removal to standard care gave better function at 90 days (common odds ratio 1.74). Published in The New England Journal of Medicine.</description></item><item><title>Remibrutinib cut relapses versus teriflunomide in two phase 3 multiple sclerosis trials</title><link>https://thelongdawn.pages.dev/d/remibrutinib-relapsing-ms-phase-3/</link><guid>https://thelongdawn.pages.dev/d/remibrutinib-relapsing-ms-phase-3/</guid>
<pubDate>Fri, 23 Oct 2026 12:00:00 +0000</pubDate><description>Phase 3 · Peer-reviewed journal. REMODEL&#8209;1 and REMODEL&#8209;2 randomly assigned 2,007 people with relapsing MS to remibrutinib (a BTK inhibitor, Novartis) or teriflunomide, an existing oral drug. Annual relapse rates were lower with remibrutinib: 0.073 versus 0.112, and 0.080 versus 0.116 (rate ratios 0.65 and 0.69). Published in The Lancet. Fewer people stopped remibrutinib because of side effects (3.1% vs 5.8%), and the authors report no liver safety concerns.</description></item><item><title>Retatrutide reduced sleep apnea severity in two phase 3 trials</title><link>https://thelongdawn.pages.dev/d/retatrutide-sleep-apnea-phase-3/</link><guid>https://thelongdawn.pages.dev/d/retatrutide-sleep-apnea-phase-3/</guid>
<pubDate>Wed, 21 Oct 2026 12:00:00 +0000</pubDate><description>Phase 3 · Peer-reviewed journal. TRIUMPH&#8209;1-OSA (243 people) and TRIUMPH&#8209;2-OSA (448 people, with type 2 diabetes) tested once-weekly retatrutide (Eli Lilly) against placebo in moderate-to-severe obstructive sleep apnea with obesity or overweight. At 80 weeks, the 9 mg dose cut breathing interruptions by 24.4 events an hour more than placebo in TRIUMPH&#8209;1-OSA, and 14.4 more in TRIUMPH&#8209;2-OSA. Published in The New England Journal of Medicine. Body weight fell 12% to 22% depending on dose and trial, versus about 5% with placebo.</description></item><item><title>Immunotherapy alone may let some rectal cancer patients skip surgery, radiation and chemotherapy</title><link>https://thelongdawn.pages.dev/d/dostarlimab-rectal-cancer-organ-sparing/</link><guid>https://thelongdawn.pages.dev/d/dostarlimab-rectal-cancer-organ-sparing/</guid>
<pubDate>Mon, 19 Oct 2026 12:00:00 +0000</pubDate><description>Approved · Regulator decision. The FDA granted accelerated approval on 19 Oct 2026 to Jemperli (dostarlimab) alone for untreated stage II or III rectal cancer that is mismatch repair deficient (dMMR) or MSI-high, about 3% of these cancers. In a phase 2 study of 154 patients, almost three-fourths had not needed surgery, radiotherapy or chemotherapy after a median follow-up of more than 2 years. In an earlier 50-patient study at Memorial Sloan Kettering, none had detectable cancer after treatment, and of 27 followed at least 3 years, one had the cancer return.</description></item><item><title>Daraxonrasib doubled median survival in previously treated pancreatic cancer, and the FDA approved it</title><link>https://thelongdawn.pages.dev/d/daraxonrasib-pancreatic-phase-3-approval/</link><guid>https://thelongdawn.pages.dev/d/daraxonrasib-pancreatic-phase-3-approval/</guid>
<pubDate>Wed, 26 Aug 2026 12:00:00 +0000</pubDate><description>Approved · Peer-reviewed journal. In the phase 3 RASolute 302 trial, 500 people with metastatic pancreatic cancer who had already been treated were randomly assigned to daraxonrasib or chemotherapy. Median overall survival was 13.2 months with daraxonrasib and 6.6 months with chemotherapy in the main group (hazard ratio 0.40). Results were published in The New England Journal of Medicine. The FDA approved daraxonrasib (brand name Rasonque, Revolution Medicines) in August 2026 for adults with metastatic pancreatic cancer who have had at least one prior systemic therapy or cannot take multi-drug chemotherapy.</description></item><item><title>A man with ALS used a brain implant at home for nearly two years to speak and work, unassisted</title><link>https://thelongdawn.pages.dev/d/braingate2-home-speech-als/</link><guid>https://thelongdawn.pages.dev/d/braingate2-home-speech-als/</guid>
<pubDate>Mon, 15 Jun 2026 12:00:00 +0000</pubDate><description>Phase 1 · Peer-reviewed journal. UC Davis, Brown and Mass General Brigham researchers reported in Nature Medicine on Casey Harrell, a BrainGate2 participant with ALS, using four implanted microelectrode arrays (256 electrodes) in the speech area of his brain. Over nearly two years he used it at home for more than 3,800 hours, communicating more than 183,000 sentences at an average of 56 words per minute, without researcher support. He rated 92% of sentences accurate or mostly correct; in controlled tests word accuracy was over 99% with a 125,000-word vocabulary.</description></item></channel></rss>
